Genomic Testing Cooperative

cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem
Publications

cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantationfor Myeloid Malignancies

The research addresses the challenge of disease relapse, a primary cause of treatment failure post-hematopoietic stem cell transplantation. By employing next-generation sequencing of cfDNA to monitor donor cell chimerism and minimal residual disease (MRD) early after transplantation, the study identifies patients at increased risk of relapse. This approach allows for potential early intervention with consolidation therapy, aiming to mitigate the risk of treatment failure.

Read More »
BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications
Article

BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology.  GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.   

Read More »
CorePath Laboratories Internalizes Genomic Testing Cooperative’s State-Of-The-Art Next-Generation Sequencing (NGS) Testing for Solid Tumors and Hematologic Neoplasms 
Press Releases

CorePath Laboratories Internalizes Genomic Testing Cooperative’s State-Of-The-Art Next-Generation Sequencing (NGS) Testing for Solid Tumors and Hematologic Neoplasms 

CorePath Laboratories is partnering with Genomic Testing Cooperative (GTC) to enhance its next-generation sequencing (NGS) capabilities for cancer diagnostics. This collaboration combines targeted DNA and RNA profiling with other pathology testing methods, providing comprehensive evaluations of patient samples. Additionally, liquid biopsy capabilities offer a non-invasive way to monitor therapy and detect relapse.

Read More »